NDA 017060 · Teva Branded Pharm
Nor-Qd
Norethindrone · Oral-28 · Progestin
Last checked: Nov 20, 2026Latest source record: Dec 3, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1973
Jan 2, 1973
Approved uses
1
Original approval plus efficacy supplements
Registered trials
137
42 Phase 3, 11 recruiting
FAERS reports
3,155
1,626 serious, 50 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 28, 2022.
INDICATIONS AND USAGE 1. Indications. Progestin-only oral contraceptives are indicated for the prevention of pregnancy. 2. Efficacy. If used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.5%. However, the typical failure rate is estimated to be closer to 5%, due to late or omitted pills. The following table lists the pregnancy rates for users of all major methods of contraception. Table 2: Percentage of Women Experiencing an Unintended Pregnancy During the First Year of Typical Use and the First Year of Perfect Use of Contraception and the Percentage Continuing Use at the End of the First Year. United States. % of Women Experiencing an Unintended Pregnancy within the First Year of Use % of Women Continuing Use at One Year 3 Method (1) Typical Use 1 (2) Perfect Use 2 (3) (4) Chance 4 85 85 Spermicides 5 26 6 40 Periodic abstinence 25 63 Calendar 9 Ovulation Method 3 Sympto-Thermal 6 2 Post-Ovulation 1 Cap 7 Parous Women 40 26 42 Nulliparous Women 20 9 56 Sponge Parous Women 40 20 42 Nulliparous Women 20 9 56 Diaphragm 7 20 6 56 Withdrawal 19 4 Condom 8 Female (Reality) 21 5 56 Male 14 3 61 Pill 5 71 Progestin only 0.5 Combined 0.1 IUDs Progesterone T 2.0 1.5 81 Copper T380A 0.8 0.6 78 LNg 20 0.1 0.1 81 Depo-Provera ® 0.3 0.3 70 Levonorgestrel Implants (Norplant ® ) 0.05 0.05 88 Female Sterilization 0.5 0.5 100 Male Sterilization 0.15 0.10 100 Emergency Contraceptive Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%. 9 Lactational Amenorrhea Method: LAM is a highly effective, temporary method of contraception. 10 Source: Trussell, J, Contraceptive Efficacy. In: Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Kowal D, Guest F, Contraceptive Technology:...
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 2, 1973 Original approval · Type 3 - New Dosage Form
1 products under this application
- NOR-QD · NORETHINDRONE 0.35MG · TABLET, ORAL-28 · Prescription · TE AB1
Clinical trials
Interventional ClinicalTrials.gov studies with "Norethindrone" as an intervention, any sponsor and status, largest first.
- Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)Pivotal-lookingTerminated
Organon and CoIndustry
NCT01656434 · 3,173 participants · Start Nov 2, 2012 · Primary completion Feb 12, 2014
Drug: NOMAC-E2; NETA-EE and 2 more · For: Contraception
- Study of Safety and Efficacy of an Oral ContraceptivePivotal-lookingCompleted
Warner ChilcottIndustry
NCT00477633 · 1,700 participants · Start Jun 2007 · Primary completion Jan 2009
Drug: Norethindrone/ethinyl estradiol · For: Contraception
Sites: Chandler, Arizona; Phoenix, Arizona; Tempe, Arizona · 63 sites in all
- Study of Safety and Efficacy of an Oral ContraceptivePivotal-lookingCompleted
Warner ChilcottIndustry
NCT00391807 · 1,683 participants · Start Nov 2006 · Primary completion Aug 2008
Drug: Norethindrone acetate/ethinyl estradiol · For: Contraception
Sites: Phoenix, Arizona; Tempe, Arizona; Tucson, Arizona · 66 sites in all
- Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in ContraceptionPivotal-lookingCompleted
Watson PharmaceuticalsIndustry
NCT01140217 · 1,659 participants · Start May 2010 · Primary completion Mar 2012
Drug: Norethindrone Acetate · For: Contraceptive Usage
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 53 sites in all
- Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast CancerPivotal-lookingCompleted
Regional Oncologic CenterAcademic, hospital or other
NCT00003771 · 1,300 participants (planned) · Start Sep 1997
Drug: therapeutic estradiol; norethindrone acetate · For: Breast Cancer; Menopausal Symptoms
Sites: Helsinki, Finland; Oslo, Norway; Warsaw, Poland · 6 sites in all
- Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for PregnancyPivotal-lookingCompleted
Sumitomo Pharma Switzerland GmbHIndustry
NCT04756037 · 1,164 participants · Start Mar 18, 2021 · Primary completion Feb 25, 2025
Drug: Relugolix Combination Therapy · For: Contraception
Sites: Mobile, Alabama; Chandler, Arizona; Mesa, Arizona · 112 sites in all
- A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or EndometriosisPivotal-lookingRecruiting
Sumitomo Pharma Switzerland GmbHIndustry
NCT05862272 · 1,000 participants (planned) · Start Aug 14, 2023 · Primary completion Jul 2029
Drug: Relugolix Combination Tablet · For: Uterine Fibroids; Endometriosis
Sites: Mobile, Alabama; Chandler, Arizona; Mesa, Arizona · 120 sites in all
- Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus ErythematosusPivotal-lookingCompleted
National Center for Research Resources (NCRR)NIH
NCT00006133 · 970 participants · Start Jun 2000
Drug: estradiol; ethinyl estradiol and 2 more · For: Systemic Lupus Erythematosus
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 17 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea251
- headache242
- off label use219
- fatigue198
- drug ineffective193
- pain170
- hot flush159
- abdominal pain151
- vaginal haemorrhage144
- diarrhoea141
- vomiting133
- arthralgia131
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 8 |
| 2006 | 3 |
| 2007 | 10 |
| 2008 | 9 |
| 2009 | 38 |
| 2010 | 50 |
| 2011 | 90 |
| 2012 | 106 |
| 2013 | 105 |
| 2014 | 184 |
| 2015 | 213 |
| 2016 | 210 |
| 2017 | 147 |
| 2018 | 162 |
| 2019 | 138 |
| 2020 | 136 |
| 2021 | 193 |
| 2022 | 307 |
| 2023 | 310 |
| 2024 | 279 |
| 2025 | 250 |
| 2026 | 206 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.
Al-Hendy A, Lukes AS, Poindexter AN, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Multicenter Study
- Medical Management of Ovarian Endometriomas: A Systematic Review and Meta-analysis.
Eberle A, Nguyen DB, Smith JP, et al. · Obstet Gynecol 2024 · Meta-Analysis, Systematic Review
- The Effect of Hormonal Treatment on Ovarian Endometriomas: A Systematic Review and Meta-Analysis.
Thiel PS, Donders F, Kobylianskii A, et al. · J Minim Invasive Gynecol 2024 · Meta-Analysis, Systematic Review
- Association of Hormonal Contraceptive Use With Adverse Health Outcomes: An Umbrella Review of Meta-analyses of Randomized Clinical Trials and Cohort Studies.
Brabaharan S, Veettil SK, Kaiser JE, et al. · JAMA Netw Open 2022 · Systematic Review
- Impact of relugolix combination therapy on functioning and quality of life in women with endometriosis-associated pain.
As-Sanie S, Abrao MS, Reznichenko G, et al. · Fertil Steril 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids.
Schlaff WD, Ackerman RT, Al-Hendy A, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Teva
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.